Beyond Diagnosis: Lifespan Trajectories and Interventions in Neurodevelopmental Disorders*
Date: October 19, 2026
Time: 3:45 pm to 5:15 pm
Room: Coral 1
Track: Cross-Cutting Special Interest Group (SIG)
Session Description
Neurodevelopmental disorders affect individuals across the lifespan, influencing biological development, social functioning, and daily life. Patients, families, and caregivers often seek anticipatory guidance to better understand long-term outcomes and prepare for key life transitions.
This Special Interest Group session will bring together experts across neurodevelopmental conditions to explore their evolving, multidimensional impact. Presentations will highlight advances in biological mechanisms, address social and functional challenges across developmental stages, and examine ethical considerations in clinical care and long-term planning. Attendees will gain practical, lifespan-informed frameworks to support anticipatory guidance and improve care for patients and families.
Learning Objectives
At the conclusion of this session, attendees will be able to:
- Describe how neurodevelopmental disorders evolve across the lifespan, including key biological, social, and functional factors.
- Evaluate medical and supportive interventions that improve outcomes over time.
- Apply ethically grounded, lifespan-informed approaches to anticipatory guidance and transition planning.
Speakers
- (Chair) Eboni Lance, MD, PhD
- (Co-Chair) Xiaochang Zhang, PhD, FANA
- (Speaker) Andrea Gropman, MD, FANA
- (Speaker) Beau Ances, MD, PhD, MSc, FANA
Beyond the Genome: Ethical, Legal, and Social Challenges in NDDs
Description
In this presentation, Dr. Gropman will discuss genomics advances in NDD diagnosis and therapy but raise ethical, legal, and social issues, including consent, equity, privacy, and stigma.
Integrated Lifespan Analysis of Down syndrome (DS) and Controls Using Blood-Based Biomarkers by NUcleic acid-Linked Immuno-Sandwich Assay (NULISA)
Description
In this presentation, Dr. Ances will look at at blood based biomarkers across the lifespan of Down syndrome.